Q32 Bio (QTTB) shares were 71% higher pre-bell Monday after the company said it has sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics (AKBA).
Belite Bio (BLTE) stock was up 17% after the company said that a late-stage trial of Tinlarebant to treat Stargardt eye disease met its primary efficacy endpoint.
Canadian Solar (CSIQ) shares were 13% higher after the company said it will resume direct oversight of its US operations.
INVO Fertility (IVF) stock was up 12% after the company said it plans to acquire fertility clinic Family Beginnings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.